Literature DB >> 8977211

Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40.

R H DeKruyff1, R S Gieni, D T Umetsu.   

Abstract

We demonstrated that two distinct pathways exist for the induction of IL-12 in APC. The first pathway for IL-12 production occurred during responses to T cell-dependent Ags such as OVA and required triggering of CD40 molecules on the APC. IL-12 production in this T cell-dependent system increased in direct proportion to Ag concentration and required TCR ligation but not CD28 costimulation. The second pathway occurred when bacterial products such as LPS or heat-killed Listeria monocytogenes were used to activate macrophages to produce IL-12 in the complete absence of T cells. In this second pathway, IL-12 production was completely independent of CD40 triggering. In both pathways, the presence of IFN-gamma was not required for induction of IL-12 synthesis when splenic adherent cells (SAC) from normal mice were used. However, addition of IFN-gamma to cultures of Th2 T cells and SAC increased IL-12 production two- to fivefold, and addition of rTNF-alpha with IFN-gamma further enhanced IL-12 production. The addition of TNF-alpha in the absence of IFN-gamma, however, had no effect on IL-12 production in the T cell-dependent pathway. Similarly, addition of TNF-alpha in the presence or the absence of IFN-gamma to cultures of LPS or heat-killed Listeria and SAC did not increase IL-12 production, but addition of IFN-gamma alone greatly enhanced IL-12 production, consistent with the idea that bacterial stimuli induce significant quantities of endogenous TNF-alpha production. These results indicate that the requirements for the induction of IL-12 production in T cell-dependent and T cell-independent responses differs mainly with regard to CD40 triggering. Furthermore, these results suggest that IL-12 production can be induced by bacterial products in patients with hyper-IgM syndrome who lack CD40 ligand expression and in those treated with soluble gp39 to interrupt CD40-CD40 ligand interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8977211

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

3.  Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets.

Authors:  H Uronen; R E Callard
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  Influence of sCD40L on gastric cancer cell lines.

Authors:  Rui Li; Wei-Chang Chen; Xue-Qin Pang; Wen-Yan Tian; Xue-Guang Zhang
Journal:  Mol Biol Rep       Date:  2011-03-20       Impact factor: 2.316

Review 5.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

Review 6.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

7.  Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.

Authors:  Hillary D Lum; Ilia N Buhtoiarov; Brian E Schmidt; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

8.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

10.  CD40 is required for the optimal induction of protective immunity to Mycobacterium avium.

Authors:  Manuela Flórido; Ana Sofia Gonçalves; M Salomé Gomes; Rui Appelberg
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.